SAN DIEGO–(BUSINESS WIRE)–Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular, inflammatory, and fibrotic diseases, is presenting new translational data on its oral 15-PGDH inhibitor program in inflammatory bowel disease (IBD), including data on MF-300 and MF-1305 at Digestive Disease Week® (DDW) 2026, which is taking place May 2-5 in Chicago, IL. In mouse models of colitis, both compounds elicited significant improvements in markers of
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
